Respiratory Distress Syndrome Market

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks? gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

Respiratory Distress Syndrome Market contains market size and forecasts of Respiratory Distress Syndrome in Global, including the following market information:

Global Respiratory Distress Syndrome Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Respiratory Distress Syndrome market was valued at 388.6 million in 2021 and is projected to reach US$ 556.5 million by 2028, at a CAGR of 5.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Poractant Alfa Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Respiratory Distress Syndrome include Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals and Noargen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Respiratory Distress Syndrome companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Respiratory Distress Syndrome Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Respiratory Distress Syndrome Market Segment Percentages, by Type, 2021 (%)

Poractant Alfa

Beractant

Calfactant

Others

Global Respiratory Distress Syndrome Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Respiratory Distress Syndrome Market Segment Percentages, by Application, 2021 (%)

Very Preterm Infants

Moderate to Late Preterm Infants

Others

Global Respiratory Distress Syndrome Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Respiratory Distress Syndrome Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Respiratory Distress Syndrome revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Respiratory Distress Syndrome revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Chiesi Farmaceutici

CR-Double Crane

ONY Biotech

AbbVie

Yuhan Corporation

JW Pharmaceuticals

Noargen